2023
Portal Hypertension in Alcohol-Associated Hepatitis
McConnell M, Iwakiri Y. Portal Hypertension in Alcohol-Associated Hepatitis. Current Hepatology Reports 2023, 22: 67-73. PMID: 37214274, PMCID: PMC10075503, DOI: 10.1007/s11901-023-00601-y.Peer-Reviewed Original ResearchAlcoholic hepatitisPortal hypertensionMajor public health problemAlcohol‐Associated HepatitisLiver-related morbidityPublic health problemReviewThis review articleIntrahepatic vasoconstrictionHospital admissionPortal inflowPerisinusoidal fibrosisHypertensionHealth problemsLiver vasculatureHepatitisClinical perspectiveMultiple possible mechanismsReview articlePossible mechanismPhlebosclerosisVasoconstrictionMorbidityInflammationAdmissionFibrosis
2020
Pathophysiology of Portal Hypertension
Iwakiri Y, Groszmann R. Pathophysiology of Portal Hypertension. 2020, 659-669. DOI: 10.1002/9781119436812.ch51.Peer-Reviewed Original ResearchPortal hypertensionGastroesophageal variceal hemorrhageHyperdynamic circulatory syndromeIntrahepatic portal hypertensionNew blood vessel formationPre-existing vascular bedExtrahepatic circulationVariceal hemorrhageCirculatory syndromeLiver cirrhosisLethal complicationVascular toneVascular bedHypertensionFrequent causeCell-specific modulationPlatelet activationBlood vessel formationOrgans/tissuesVasoconstrictor moleculesCirrhosisTherapeutic purposesVessel formationPathophysiologySubsequent development
2017
Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]
Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, Davies N, Sharma V, Iwakiri Y, Jalan R. Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]. Journal Of Hepatology 2017, 67: 1124. PMID: 28893453, DOI: 10.1016/j.jhep.2017.08.004.Peer-Reviewed Original Research
2014
Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension
Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed Fel Z, Davies N, Sharma V, Iwakiri Y, Jalan R. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. Journal Of Hepatology 2014, 62: 325-331. PMID: 25152204, PMCID: PMC4530584, DOI: 10.1016/j.jhep.2014.08.024.Peer-Reviewed Original ResearchConceptsDDAH-1 expressionMean arterial pressurePortal hypertensionENOS activityDDAH-1Farnesoid X receptor (FXR) agonismFXR agonist obeticholic acidPortal pressure reductionAgonist obeticholic acidPortal pressure measurementsHealthy liver tissueArterial pressureENOS inhibitorHuman cirrhosisBDL ratsObeticholic acidSpecific molecular targetsPlasma ALTReceptor agonismSaline controlsCirrhosisCirrhosis ratsHypertensionOA treatmentTranslational studiesVascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions
Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions. Journal Of Hepatology 2014, 61: 912-924. PMID: 24911462, PMCID: PMC4346093, DOI: 10.1016/j.jhep.2014.05.047.BooksConceptsChronic liver diseasePortal hypertensionLiver diseaseLiver fibrosis/cirrhosisVascular cellsMesenteric vascular circulationFibrosis/cirrhosisDynamic vascular changesCollateral vessel formationHepatic stellate cellsSinusoidal endothelial cellsGrowth factor pathwaysGrowth factor βExtrahepatic circulationExtrahepatic vasculatureArterial vasodilationLiver injuryVascular changesVasoactive peptidesHypertensionVascular pathobiologySystemic circulationStellate cellsVascular processesLiver vasculaturePathophysiology of Portal Hypertension
Iwakiri Y. Pathophysiology of Portal Hypertension. Clinics In Liver Disease 2014, 18: 281-291. PMID: 24679494, PMCID: PMC3971388, DOI: 10.1016/j.cld.2013.12.001.BooksConceptsPortal hypertensionBlood flowHyperdynamic circulatory syndromeIntrahepatic vascular resistancePortal blood flowVascular resistanceArterial vasodilationCirculatory syndromeEsophageal varicesLiver cirrhosisMajor complicationsLiver diseaseCollateral vesselsPortal circulationSystemic circulationHypertensionPathologic conditionsClinical researchCirrhosisVaricesVasodilationAscitesComplicationsPathophysiologySyndromePathophysiology of Portal Hypertension
Iwakiri Y, Groszmann R. Pathophysiology of Portal Hypertension. 2014, 3-14. DOI: 10.1007/978-1-4939-0002-2_1.Peer-Reviewed Original ResearchPortal hypertensionLiver diseaseHyperdynamic splanchnic circulationHepatic vascular resistanceSerious liver diseaseExtrahepatic diseaseGastroesophageal varicesVascular resistanceHemodynamic abnormalitiesSplanchnic circulationLethal complicationCirculatory derangementsHypertensionDiseaseCurrent knowledgeVaricesAscitesComplicationsHemorrhageDerangementPathophysiologyRegulatory mechanismsAbnormalitiesFunctional aspects
2013
The lymphatic vascular system in liver diseases: its role in ascites formation
Chung C, Iwakiri Y. The lymphatic vascular system in liver diseases: its role in ascites formation. Clinical And Molecular Hepatology 2013, 19: 99-104. PMID: 23837133, PMCID: PMC3701854, DOI: 10.3350/cmh.2013.19.2.99.BooksConceptsLiver fibrosis/cirrhosisFibrosis/cirrhosisLiver diseasePortal hypertensionAscites formationVascular systemLymphatic vascular systemNormal vascular functionPotential therapeutic targetVascular functionLiver tumorsTherapeutic targetDiseaseLymphatic systemTumor metastasisCirrhosisHypertensionLymphatic vesselsCirculatory systemPathogenesisLymphangiogenesisMetastasisTumorsLiverRole
2012
Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure
Huang H, Haq O, Utsumi T, Sethasine S, Abraldes JG, Groszmann RJ, Iwakiri Y. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. Journal Of Cellular And Molecular Medicine 2012, 16: 1125-1133. PMID: 21801303, PMCID: PMC3213314, DOI: 10.1111/j.1582-4934.2011.01399.x.Peer-Reviewed Original ResearchConceptsPlasma VEGF levelsPortal pressureVEGF levelsPortal hypertensionIntestinal VEGFDevelopment of cirrhosisFibrosis/cirrhosisAge-matched controlsGroups of ratsEnd of exposureCirrhosisRatsSignificant positive correlationWeeksHypertensionVEGFInhalationPositive correlationDifferent stagesCarbon tetrachlorideLevelsPathologyControl
2011
Endothelial dysfunction in the regulation of cirrhosis and portal hypertension
Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver International 2011, 32: 199-213. PMID: 21745318, PMCID: PMC3676636, DOI: 10.1111/j.1478-3231.2011.02579.x.BooksConceptsLiver sinusoidal endothelial cellsPortal hypertensionEndothelial dysfunctionArterial vasodilationPortosystemic collateral vesselsProduction of vasodilatorsDevelopment of cirrhosisCollateral vessel formationPathological vascular eventsSinusoidal endothelial cellsExtrahepatic circulationIntrahepatic resistanceOesophageal varicesVascular eventsVascular resistanceVasodilator moleculeCollateral vesselsSinusoidal microcirculationPortal veinHypertensionSystemic circulationBlood flowCirrhosisDysfunctionNitric oxide
2010
The Systemic and Splanchnic Circulations
Iwakiri Y. The Systemic and Splanchnic Circulations. Clinical Gastroenterology 2010, 305-321. DOI: 10.1007/978-1-60761-866-9_15.Peer-Reviewed Original ResearchPortal hypertensionArterial vasodilatationSplanchnic circulationSystemic circulationNitric oxideInitiation of vasodilatationSystemic hemodynamic abnormalitiesDevelopment of complicationsSplanchnic blood flowProgressive vasodilatationHemodynamic abnormalitiesIntestinal microcirculationLiver cirrhosisLiver diseaseVasodilator moleculeHypertensionVasodilatationBlood flowCirrhosisPatientsMolecular mechanismsKey eventsSensory mechanismsCirculationComplications
2008
Vascular biology and pathobiology of the liver: Report of a single‐topic symposium
Iwakiri Y, Grisham M, Shah V. Vascular biology and pathobiology of the liver: Report of a single‐topic symposium. Hepatology 2008, 47: 1754-1763. PMID: 18393322, PMCID: PMC2724750, DOI: 10.1002/hep.22203.BooksConceptsPortal hypertensionVascular biologyIschemia-reperfusion injurySingle Topic ConferenceMajority of morbidityClinical sequelaeIR injurySpecific disease syndromesLiver diseaseVascular syndromesVascular diseaseVascular cell signalingHypertensionDisease syndromeLiver cellsSyndromeMajor vascular defectsLiverVascular defectsInjuryDiseasePathobiologyAmerican AssociationCell signalingCirrhosis
2007
The Molecules
Iwakiri Y. The Molecules. Journal Of Clinical Gastroenterology 2007, 41: s288-s294. PMID: 17975478, DOI: 10.1097/mcg.0b013e3181468b4c.BooksMeSH KeywordsAdrenomedullinAnimalsArteriesBiological FactorsCannabinoid Receptor ModulatorsCarbon MonoxideCoenzymesEndothelium, VascularEpoprostenolHumansHydrogen SulfideHypertension, PortalLiver CirrhosisNitric OxideNitric Oxide Synthase Type IIIPortal PressureSplanchnic CirculationTumor Necrosis Factor-alphaUp-RegulationVascular Endothelial Growth Factor AVasodilationVasodilator AgentsVascular endothelial dysfunction in cirrhosis
Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. Journal Of Hepatology 2007, 46: 927-934. PMID: 17391799, DOI: 10.1016/j.jhep.2007.02.006.BooksConceptsEndothelium-dependent relaxationEndothelial dysfunctionSinusoidal endothelial cellsPortal hypertensionVascular nitric oxide levelsVascular endothelial dysfunctionNitric oxide levelsSEC dysfunctionVascular resistanceEarly key eventSplanchnic circulationLiver cirrhosisVasodilator moleculeLiver microcirculationSystemic circulationOxide levelsCirrhosisDysfunctionEndothelial cellsHypertensionMultiple diseasesKey eventsArteryMicrocirculationDisease
2006
The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule
Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology 2006, 43: s121-s131. PMID: 16447289, DOI: 10.1002/hep.20993.BooksMeSH KeywordsAdrenomedullinAnimalsBiological FactorsBlood PressureCannabinoid Receptor ModulatorsCarbon MonoxideChronic DiseaseDisease Models, AnimalEndothelium, VascularHumansHydrogen SulfideHypertension, PortalLiverLiver DiseasesNitric OxidePeptidesSplanchnic CirculationTumor Necrosis Factor-alphaVasodilationConceptsHyperdynamic circulatory syndromeChronic liver diseaseCirculatory syndromeLiver diseaseVasodilator moleculeClinical observationsExperimental modelComplex pathophysiological mechanismsHyperdynamic circulationProgressive vasodilatationPortal hypertensionPathophysiological mechanismsVascular abnormalitiesComplex syndromeMultiple organsPatientsNitric oxideSyndromeVasodilatationDiseaseDetrimental effectsHypertensionAbnormalitiesComplex mechanisms
2004
The paradox: vasoconstriction and vasodilation
Iwakiri Y, Groszmann R. The paradox: vasoconstriction and vasodilation. 2004, 57-67. DOI: 10.1007/978-94-007-1042-9_7.Peer-Reviewed Original ResearchPortal hypertensionLiver diseaseVascular toneNitric oxideHyperdynamic circulatory syndromeChronic liver diseaseHomeostatic mechanismsBody's homeostatic mechanismsCirculatory syndromeImpaired oxygenationElectrolyte imbalanceHomeostatic functionsKey moleculesHypertensionProgressive alterationDiseaseToneVasoconstrictionVasodilationPatientsPatients1Major rolePathogenesisSyndromeAbnormalities
2001
The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension
Iwakiri Y, Tsai M, Sessa W, Groszmann R. The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension. Gastroenterology 2001, 120: a9. DOI: 10.1016/s0016-5085(08)80044-3.Peer-Reviewed Original ResearchThe phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension
IWAKIRI Y, TSAI M, SESSA W, GROSZMANN R. The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension. Gastroenterology 2001, 120: a9-a9. DOI: 10.1016/s0016-5085(01)80044-5.Peer-Reviewed Original Research